Drug Information

Drug General Information
Drug ID
D04EON
Former ID
DIB010565
Drug Name
BAL-101553
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1/2 [525257]
Company
Basilea Pharmaceutica International Ltd
Canonical SMILES
Cl.Cl.c1(c(non1)NCCC#N)c1n(c2ccccc2n1)CC(=O)c1ccc(cc1)N<br />C(=O)[C@@H](N)CCCCN
Target and Pathway
Target(s) Tubulin beta Target Info Inhibitor [533035]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 525257ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors.
Ref 533035Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.